MULTIDRUG RESISTANCE PROTEIN: P-GLYCOPROTEIN - Drug Transporters: Molecular Characterization and Role in Drug Disposition - page 253

71. Liu R, Sharom FJ. 1997. Fluorescence studies on the nucleotide binding domains of the
P-glycoprotein multidrug transporter. Biochemistry 36:2836-2843.
72. Urbatsch IL, Sankaran B, Weber J, Senior AE. 1995. P-glycoprotein is stably inhibited by
vanadate-induced trapping of nucleotide at a single catalytic site. J Biol Chem 270:19383-
19390.
73. Loo TW, Clarke DM. 1995. Covalent modification of human P-glycoprotein mutants
containing a single cysteine in either nucleotide-binding fold abolishes drug-stimulated
ATPase activity. J Biol Chem 270:22957-22961.
74. Liu R, Sharom FJ. 1996. Site-directed fluorescence labeling of P-glycoprotein on cysteine
residues in the nucleotide binding domains. Biochemistry 35:11865-11873.
75. Sharom FJ, DiDiodato G, Yu X, Ashbourne KJ. 1995. Interaction of the P-glycoprotein
multidrug transporter with peptides and ionophores. J Biol Chem 270:10334-10341.
76. Gottesman MM, Pastan I, Ambudkar SV. 1996. P-glycoprotein and multidrug resistance.
Curr Opin Genet Dev 6:610-617.
77. Ambudkar SV, Lelong IH, Zhang J, Cardarelli CO, Gottesman MM, Pastan I. 1992.
Partial purification and reconstitution of the human multidrug-resistance pump: charac-
terization of the drug-stimulatable ATP hydrolysis. Proc Natl Acad SciUSA89:8472-
8476.
78. Doige CA, Yu X, Sharom FJ. 1993. The effects of lipids and detergents on ATPase-active
P-glycoprotein. Biochim Biophys Acta 1146:65-72.
79. Senior AE, al-Shawi MK, Urbatsch IL. 1995. The catalytic cycle of P-glycoprotein. FEBS
Lett 377:285-289.
80. Smith CA, Rayment I. 1996. X-ray structure of the magnesium(II) · ADP · vanadate com-
plex of the Dictyostelium discoideum myosin motor domain to 1.9 A resolution. Bio-
chemistry 35:5404-5417.
81. Liu R, Siemiarczuk A, Sharom FJ. 2000. Intrinsic fluorescence of the P-glycoprotein mul-
tidrug transporter: sensitivity of tryptophan residues to binding of drugs and nucleotides.
Biochemistry 39:14927-14938.
82. Delannoy S, Urbatsch IL, Tombline G, Senior AE, Vogel PD. 2005. Nucleotide binding
to the multidrug resistance P-glycoprotein as studied by ESR spectroscopy. Biochemistry
44:14010-14019.
83. Qu Q, Russell PL, Sharom FJ. 2003. Stoichiometry and affinity of nucleotide binding to
P-glycoprotein during the catalytic cycle. Biochemistry 42:1170-1177.
84. Safa AR. 1998. Photoaffinity labels for characterizing drug interaction sites of P-
glycoprotein. Methods Enzymol 292:289-307.
85. Safa AR. 1999. Photoaffinity analogs for multidrug resistance-related transporters and
their use in identifying chemosensitizers. Drug Resist Updates 2:371-381.
86. Martin C, Berridge G, Higgins CF, Callaghan R. 1997. The multi-drug resistance rever-
sal agent SR33557 and modulation of vinca alkaloid binding to P-glycoprotein by an
allosteric interaction. Br J Pharmacol 122:765-771.
87. Taylor JC, Ferry DR, Higgins CF, Callaghan R. 1999. The equilibrium and kinetic drug-
binding properties of the mouse P-gp1a and P-gp1b P-glycoproteins are similar. Br
J Cancer 81:783-789.
88. Martin C, Berridge G, Mistry P, Higgins C, Charlton P, Callaghan R. 2000. drug-binding
sites on P-glycoprotein are altered by ATP binding prior to nucleotide hydrolysis. Bio-
chemistry 39:11901-11906.